Lung Cancer Clinical Trial
Official title:
A Randomized Clinical Trial of the Efficacy of an Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery
To test the effectiveness of the interactive voice response telephone system with a
triage/feedback component that incorporates timely symptom assessment, feedback to
physicians, critical treatment guidelines for managing selected symptoms (distress, sleep
disturbance, shortness of breath, constipation, and pain) in a cohort of cancer patients
during the first month post-thoracic surgery.
This interactive voice response system (IVR) will be evaluated in a randomized clinical
trial with an intervention group (IVR symptom assessment with triage) and a control group
(IVR symptom assessment only).
We hypotheses that:
1. Patients in the MDASI-IVR plus triage group will have less symptom burden (less symptom
severity, less symptom related interference, and better satisfaction of symptom
control, better physical and emotional well-being) over the month of the trial compared
to the control group.
2. Patients in the MDASI-IVR plus triage group will have more frequent documentation of
symptom management in line with treatment guidelines compared to the control group.
The IVRS is a special telephone system that calls patients and asks questions about
symptoms. The system can record and report severe symptoms to a patient's doctor by e-mail,
fax, or pager. All patients are encouraged to report and discuss any severe symptoms to your
treating clinicians.
If you agree to take part in this study, you will be randomly assigned (as in the toss of a
coin) to 1 of 2 groups. Participants in one group will complete symptom surveys on the IVRS.
Participants in the other group will complete symptom surveys on the IVRS, and (in addition)
a report of severe symptoms will be sent to their doctor or nurse.
All participants will initially be asked to complete 2 surveys (before surgery) that will
ask about any symptoms you may be having and your general quality of life. It will take
about 10 minutes to complete both surveys. You will also be asked to provide some
demographic information, such as your age, gender, employment status, and ethnicity.
Before you are discharged from the hospital (after your surgery), a member of the study
staff will visit you and teach you how to use the IVRS system, and you will then continue
participation according to your assigned group.
After you are discharged from the hospital, the system will be set up to call you (all
participants) twice a week until 1 month after your surgery. It will be automated to ask you
to rate 14 types of symptoms (such as pain, fatigue, nausea, sleep disturbance and 6 other
items, such as how your symptoms interfere with your day-to-day activity, mood, and
enjoyment of life) on a scale from 0 to 10. Zero (0) means that the symptom is not present,
and 10 means that you are experiencing the symptom at its worst. The call should last from
3-5 minutes. For participants in the other group, a symptom report will also be sent to your
doctor or nurse.
One month after surgery, you will have a phone call from a member of the research staff.
During this phone call, you will be asked to provide additional information about the
symptoms you experienced and how you managed them.This phone call will last about 20
minutes. If you are not able to be reached by research staff the first time you are called,
you will be called again at another time between the 5th and 6th week after your surgery.
THIS IS AN INVESTIGATIONAL STUDY. Up to 130 patients (65 in each group) will take part in
this study. All will be enrolled at M. D. Anderson.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|